We would love to hear your thoughts about our site and services, please take our survey here.
DTW:
“ I'm not sure how this will operate if she is based in the US.”
Indeed, I find this interesting and have great difficulty imagining that she will move to the UK. Obviously she can get some air miles in and perhaps we have to trust that her new role can be executed from the States. In any event it would appear that we are becoming ever more USA leaning…
GLA
I do wonder if Avct et al already know or have a very good idea of mtd, this in my opinion would not need to be an RNS until totally agreed and finally signed off by all or became public knowledge.
Timelines are no longer entirely controlled by Avacta, that said Fiona has often mentioned her wish to expedite the process (who on earth wouldn’t?) this will be groundbreaking.
As a certain knowledgeable commentator has already suggested why not establish mtd at end of C 6 and continue through 7 to provide some headroom re. the platform as a whole as an aside?
To be honest none of us know for sure but next week could be definitive.
GLA holders.
D T W
Yes, exactly that it was a response from an audience question and I would describe his response exactly as you have. When the question was asked I thought to myself he may not want to answer this but he seemed very pleased to answer. I’m hoping it’s a strong option for them.
Https://twitter.com/avacta/status/1660570838481924097?s=61&t=9klymDu_TGvr7yv5rGN8dA
Assume it’s this:
https://www.businesstelegraph.co.uk/uk-partnerships-with-life-sciences-groups-threatened-by-nhs-pressures/
GLA
“ The poster being presented today at AACR, ‘AVA3996, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein-alpha (FAP-a) mediated cleavage’, is now available to download at: avacta.com/about/resource… #AVCT”
This in part by the above is fascinating, certainly proves it can be done.
https://www.americanscientist.org/article/fighting-cancer-through-the-study-of-sarcomas
https://avacta.com/interview-with-victoria-statham-vp-intellectual-property-legal-therapeutics/
https://elifesciences.org/articles/24903
“ Future challenges are to test the Affimer in even more applications and to encourage its wider use by researchers, alongside other alternative binding proteins, as as replacements for some antibodies. This could ultimately lead to the development of faster and more efficient diagnostic, imaging and therapeutic tests“
“The results of the tests show that the Affimer behaves in the same way as antibodies, and sometimes works more effectively. Tiede et al. show that an Affimer can help to reveal how a particular molecule works within a cell, to create detailed pictures of molecules in cells and tissues, and to identify a tumour. It can also be used alongside a new technique called ‘super-resolution microscopy’ that allows researchers to watch the activity of individual molecules”
GLA
https://twitter.com/mobilestreams/status/1494584257536266241?s=21
GLA
For those not familiar with AVCT there is strong evidence that they have a way of delivering chemotherapy into humans without the usual awful side effects.
I hold mos and avct and my intention is to hold both until taken over.
My first and last post on this thread.
GLA
gmcc, if I may add, I also found this line interesting from the last rns:
“aiming to extend the therapeutic benefits to all cancer patients.”
GLA